Uxin Limited Securities Litigation

According to the Complaint, Uxin is a used car e-commerce platform in China. The Company has two segments: Uxin Auction (or 2B business) sells used cars to dealers, and Uxin Used Car (or 2C business) sells used cars to consumers.

See Case Details »

SI Financial Group, Inc. Securities Litigation

According to the Complaint, SI Financial Group, Inc. ("SI FI" or the "Company") is the parent holding company for Savings Institute Bank and Trust Company (the "Bank"). The Bank operates as a community-oriented financial institution offering a full range of financial services to consumers and businesses in its market area, including life
insurance and annuities.

See Case Details »

Immunomedics, Inc. Securities Litigation (2019)

Plaintiff's law firm issued a press release on February 8, 2019, announcing the filing of the lawsuit. According to the press release, Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

See Case Details »

Western Gas Partners, LP Securities Litigation

According to the Complaint, this action stems from a proposed transaction announced on November 8, 2018 (the "Proposed Transaction"), pursuant to which Western Gas Partners, LP ("WES" or the "Partnership") will be acquired by Western Gas Equity Partners, LP and its affiliates ("WGP").

See Case Details »

Celgene Corporation Securities Litigation (2019)

According to the Complaint, Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases.

See Case Details »